Sign In
Buy ZTS
$74.17
-1.16 (-1.54%)
At Close: Jul 22, 2026
Why Zoetis (ZTS) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 14'th Oct 2025
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
02:11pm, Monday, 13'th Oct 2025
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
04:15pm, Friday, 10'th Oct 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.
Zoetis Declares Fourth Quarter 2025 Dividend
04:15pm, Thursday, 09'th Oct 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will
2 Magnificent Dividend Stocks to Buy Now and Hold Forever
07:15am, Wednesday, 08'th Oct 2025
Few stocks are worth holding onto forever. Those that do tend to have certain traits, including a strong position in an industry with excellent growth prospects and strong, consistent financial result
My 2 Favorite Stocks to Buy Right Now
04:20am, Sunday, 05'th Oct 2025
The S&P 500 continues to advance to new all-time highs, delivering total returns of 15.2% so far in 2025. However, much of this run stems from the "Magnificent Seven" and other massive technology stoc
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
07:00pm, Thursday, 02'nd Oct 2025
Explore the exciting world of Zoetis (ZTS -0.31%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends a
Top 15 High-Growth Dividend Stocks For October 2025
10:58pm, Wednesday, 01'st Oct 2025
The Top 15 High-Growth Dividend Stock list for October 2025 targets a 12% long-term return, despite underperforming SPY and VIG in September. These 15 stocks offer a 1.4% average yield and have grown
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 29'th Sep 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks is more attractive t
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
07:16pm, Friday, 26'th Sep 2025
Zoetis (ZTS) concluded the recent trading session at $143.5, signifying a +1.68% move from its prior day's close.
Pet Pain For Investor Gain
10:19am, Friday, 26'th Sep 2025
ZTS is fundamentally a companion animal company, with the segment driving 68% of 2024 revenue and projected to reach 71% by 2030, fueled by aging pet demographics in the US. OA pain franchise, Librela
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
08:30am, Tuesday, 23'rd Sep 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
07:15pm, Monday, 15'th Sep 2025
In the closing of the recent trading day, Zoetis (ZTS) stood at $146.25, denoting a -1.32% move from the preceding trading day.
Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain
10:56am, Monday, 15'th Sep 2025
ZTS secures CVMP's positive opinion recommending the approval of Portela, a long-acting OA pain therapy for cats, with final decision expected in late 2025.
